Argenx (ARGX)’ treatment of idiopathic inflammatory myopathy was granted FDA orphan designation, according to a post to the agency’s site.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx’s Long-term Safety Study on Efgartigimod for Pediatric Myasthenia Gravis: Key Insights for Investors
- Argenx’s Promising CIDP Treatment: A Closer Look at the Efgartigimod PH20 SC Study
- Argenx’s Efgartigimod Study: A Potential Breakthrough for Lupus Nephritis
- Argenx price target raised to EUR 700 from EUR 680 at Barclays
- Argenx price target raised to EUR 730 from EUR 700 at JPMorgan